Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, ...
Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...
Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month. Overall, the long-term thesis for owning Array's stock continues to look intact. If you ...
Hi, good morning everybody and thank you for joining us for Day Three, our final day. Here at Annual BofA Merrill Healthcare Conference in Vegas. We are certainly excited to be able to host Array ...
* Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million * Array Biopharma Inc - loan agreement also provides for ...
The following audio is from a conference call that will begin on November 04, 2015 at 09:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. If you ...
* Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing Source text: Further company coverage: ...
Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Dow and Nasdaq finished January trading with a mixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results